UMass Medical School researchers to evaluate treatment options for early COVID-19 infection
UMass Medical School Communications July 08, 2021
UMass Medical School is participating in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which is being led by the AIDS Clinical Trials Group (ACTG). ACTIV-2 includes both Phase II and Phase III evaluations of investigational agents for treating early COVID-19.
To qualify for ACTIV-2, participants must have tested positive for SARS-CoV-2 in the outpatient setting within 10 days and started experiencing symptoms within eight days of enrolling.
“The goal of ACTIV-2 is to identify treatments that can keep people who acquire COVID-19 from getting sicker and requiring hospitalization,” said Robert W. Finberg, MD, distinguished professor of medicine and lead investigator of the Medical School’s ACTIV-2 trial site. “People living in central Massachusetts who have recently been diagnosed with COVID-19 a
California
United-states
San-diego
Massachusetts
Robertw-finberg
Los-angeles
Davey-smith
Josephj-eron
Judith-currier
Erics-daar
David-alain-wohl
University-of-california